1 Update to Post Exclusivity Pediatric Adverse Event Review: Atorvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

Slides:

Advertisements

Similar presentations

Dermatologic and Ophthalmic Drugs Advisory Committee July 12, Clinical Wrap-Up Denise Cook, M.D. Medical Officer Division of Dermatology and Dental.

Advertisements

Farxiga™ - Dapagliflozin

1 One Year Post Exclusivity Adverse Event Review: Fentanyl Transdermal System Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting.

Clinical question: When do you get statin induced myopathy?

Diagnosis and Treatment of Dyslipidemia  New guidelines are based on the “Adult Treatment Plan III (ATP III)” 2004  Focus = multiple risk factor assessment.

1 One Year Post Exclusivity Adverse Event Review: Atovaquone-Proguanil Pediatric Advisory Committee Meeting February 14, 2005 Alan M. Shapiro, MD, PhD,

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.

1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.

Afrezza® – inhaled human insulin

{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.

Clinical experience with ezetimibe/simvastatin in a Mediterranean population The SETTLE Study I. Migdalis a, A. Efthimiadis b, St. Pappas c, D. Alexopoulos.

Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.

1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.

Hperlipidemia:- Treatment and Management Presented by:- Dr. Tewari.

10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.

Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.

Praluent® - alirocumab

Pediatric Advisory Committee April 11, Update to the Committee: Oxybutynin Central Anticholinergic Effects Pediatric Advisory Committee Meeting.

DRAFT SLIDES FOR NDA ADVISORY COMMITTEE PRESENATIONS.

Augmentin ES  for acute otitis media Mamodikoe Makhene, M.D. Prepared for Anti-infectives Advisory Committee meeting January 30, 2001.

Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, Overview Isotretinoin Pregnancy Exposures:

Dyslipidemia.  Dyslipidemia is elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high- density lipoprotein level that contributes.

Regulatory History of Sibutramine Eric Colman, MD Division of Metabolism and Endocrinology Products CDER - FDA.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

1 One Year Post Exclusivity Adverse Event Review: Fexofenadine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

1 One Year Post-Exclusivity Adverse Event Review: Paricalcitol, Zolmitriptan, Dorzolamide, and Leflunomide Pediatric Advisory Committee Meeting June 29,

1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.

Case 15 Andrea De Mesa. Patient history A 44 y/o male, single, undergoes cardiovascular screening on advice of his attending physician. He is a smoker.

Orlistat 60 mg Joint Meeting Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees January 23, 2006 Andrea Leonard-Segal, M.D.

1 One Year Post Exclusivity Adverse Event Review: Esmolol Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer Division.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Sidney M. Wolfe M.D and Sherri Shubin M.D., M.P.H. Public Citizen’s Health Research Group FDA Drug Safety and Risk Management and Dermatologic and Ophthalmic.

CRDAC Questions June 15, 2005 Antihypertensive drugs, with few exceptions, have no outcome claim in their labeling. This is inconsistent with their approval.

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

Mevacor 20 mg Joint Meeting Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees December 13, 2007 Andrea Leonard-Segal, M.D.

1 One Year Post Exclusivity Adverse Event Review: Carboplatin Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

History of Pediatric Labeling

1 One Year Post-Exclusivity Adverse Event Review: Rosiglitazone Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 One Year Post-Exclusivity Adverse Event Review: Insulin Aspart Recombinant Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs,

Endocrinologic & Metabolic Drugs Advisory Committee Meeting

Food and Drug Administration Amendments Act of 2007 Reauthorization of Pediatric Initiatives Lisa L. Mathis, M.D. Pediatric and Maternal Health Staff Office.

Case I A 47 old male presents to your office for a yearly checkup. He smokes 40 cigarette/day, and examination detect wheezy chest and bronchospasm. His.

Oxypurinol for Symptomatic Gout in Allopurinol Intolerant Patients Lourdes Villalba, M.D. DAAODP, CDER, FDA Arthritis Advisory Committee Meeting June 2,

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Initiatives Drive Pediatric Drug Development January 30, 2002.

Modafinil for the Treatment of ADHD Paul J. Andreason, MD Acting Deputy Director Division of Psychiatry Products Center for Drug Evaluation and Research,

Manufacturer: Amgen Inc FDA Approval Date: August 27, 2015

Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.

Zelnorm ® (tegaserod) Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S.

1 Overview of Pediatric Safety Reporting and Role of the Committee Pediatric Advisory Committee Meeting November 18, 2005 Solomon Iyasu, M.D., M.P.H. Acting.

Review Update: QT Prolongation with Citalopram and Escitalopram Pediatric Advisory Committee Meeting November 16, 2006 Prepared by M. Lisa Jones, MD Division.

1 Update to Post-Exclusivity Pediatric Adverse Event Review: Oxybutynin Pediatric Advisory Committee Meeting November 16, 2006 Lisa Mathis, MD, Associate.

Overview of Pediatric Drug Development Dianne Murphy, MD Director Office of Counterterrorism and Pediatric Drug Development Center for Drug Evaluation.

C-1 Safety Results S. aureus Bacteremia and Endocarditis Study Gloria Vigliani, M.D. Vice President, Medical Strategy Cubist Pharmaceuticals.

1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 Joint NDAC/EMDAC Meeting January 13, 2005 Mevacor TM Daily 20 mg Tablets Rx-to-OTC Switch Daiva Shetty, M.D. Division of Over-the-Counter Drug Products.

Pediatric Advisory Committee: Overview of Role and Evolution of Process Dr. Dianne Murphy Director, Office of Pediatric Therapeutics, OC, FDA November.

1 One Year Post Exclusivity Adverse Event Review: Glyburide-Metformin Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP.

Viagra (sildenafil citrate): Extensive Clinical and Post-Marketing Experience Michael Sweeney, MD Senior Medical Director Pfizer Inc.

Case 1: Elevated LDL-C in a Young Adult. Page 2 of 10 *DALY; disability-adjusted life years Routine checkup:  Age:33 years  Sex: male  Status: Except.

Intensive Statin Recommendations

Major classes of drugs to reduce lipids

Train-the-Trainer Cases

Train-the-Trainer Cases

Train-the-Trainer Cases

Dyslipidemia And Diabetes

Section 6: Update on lipid treatment guidelines

Presentation transcript:

1 Update to Post Exclusivity Pediatric Adverse Event Review: Atorvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting Medical Team Leader Pediatric and Maternal Health Staff Office of New Drugs Center for Drug Evaluation and Research Food and Drug Administration

2 Background Drug Information Drug: Lipitor ® (atorvastatin) Therapeutic Category: lipid-lowering agent Sponsor: Pfizer Original Market Approval: December 17, 1996 Pediatric Exclusivity Granted: February 22, 2002 Mechanism of action: inhibitor of HMG-CoA reductase

3 Background Drug Information Pediatric Indication: adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and post-menarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present –LDL-C remains >190 mg/dl or –LDL-C remains >160 mg/dl and there is a positive family history of premature CVD or >2 CVD risk factors are present Pediatric Dosage: –initial dose 10 mg daily with maximum 20 mg daily

4 Background Drug Information Pediatric Indication: to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable. Dosage: mg daily

5 Atorvastatin: Pediatric Labeling Changes Patient Package Insert approved May, 2004; updated June, 2006 –Indicated for children over 10 years whose cholesterol does not come down enough with exercise and low fat diet alone –Keep out of reach of children

6 Atorvastatin: Pediatric Drug Use Trends 1 Pediatric use is small (< 0.1% of total number of prescriptions dispensed in retail pharmacies) # of pediatric prescriptions dispensed by year: –in 2002: 36,668 prescriptions –in 2003: 36,894 –in 2004: 37,101 –in 2005: 32,381 1 Verispan, Vector One ® : National (VONA), data extracted Aug 2006

7 Atorvastatin: Pediatric Adverse Events None during the one year post exclusivity (2/22/02-3/22/03) 12 (0.15% of total reports for all ages) during the subsequent three year period (3/22/03-8/22/06) –All serious, including one death –9 post-natal reports in children 2-16 years (3 accidental ingestions; 6 other reports) –3 in utero exposures (included 1 stillbirth); pregnancy category X

8 Atorvastatin: Pediatric Other Post-Natal Adverse Events 6 other reports in patients aged 4-16 years –iron-deficiency anemia (16 year old female; anemia labeled) –pancreatitis (labeled) –muscle stiffness, chest pain and elevated CPK level (labeled) –bone marrow suppression (no details provided; unlabeled) –bronchospasm (positive rechallenge; unlabeled) –hemoptysis (diffuse pulmonary alveolar hemorrhage; unlabeled)

9 Bronchospasm Case Report Foreign report 4 year old male Diagnosis: myocardial ischemia Medications: –simvastatin since 3/04; duration unknown –atorvastatin since 4/04; duration unknown –clopidogrel and aspirin Bronchospasm (reversible): noted 3/04; positive rechallenge x3 (no details provided); intervention not reported but resolved 5/04

10 Hemoptysis Case Report Foreign report 16 year old male Diagnosis: familial hypercholesterolemia Medications: –atorvastatin: 6/04-1/05 –nicotinic acid: 6/04-12/04 Hemoptysis 12/04; bronchoscopy: diffuse pulmonary alveolar hemorrhage; echocardiogram: cardiomegaly; diagnosed with moderate heart failure

11 Atorvastatin: Pediatric Other Post-Natal Adverse Events Above adverse events that are unlabeled are confounded by underlying illness, concomitant medications and/or insufficient information.

12 Atorvastatin: In Utero Exposures Congenital blindness; atorvastatin during first 8 weeks of pregnancy. Congenital hepatomegaly, single functional kidney and stillbirth at 33 weeks gestational age; maternal diabetes mellitus; insulin, gliclazide, metformin and atorvastatin: unknown start date but last 3 drugs discontinued 2.5 months prior to delivery. “Born with myopathy”; paternal exposure to atorvastatin 2-3 months prior to conception.

13 Summary: Atorvastatin Pediatric unlabeled post-natal adverse events: no new safety signal identified: few reports, single cases, confounded or insufficient information In utero exposures: Pregnancy category X The FDA recommends routine monitoring of atorvastatin for AEs in all populations Does the Advisory Committee concur?

14 Acknowledgements OSE Jennie Chang David Moeny Jo Wyeth Rosemary Johann-Liang PMHS Lisa Mathis Kristin Phucas DMEP Eric Colman Eileen Craig